nice post.
I have a growing impending gut feeling that the regen business units could eventually be acquired or deal done with tavr company - normally when i have this feeling has become a reality in my past experiences, but not always. I see a lot of tavr players are buying & financing big stakes in companies with technologies that this company. It would seem to be a straigh forward & rational for a tavr company to have this in their portfolio and company then would not be no need to rationalise their R&D business but could evenexpand the development of the technology with rich financing these companies have - I wonder how this would be taken by us shareholders if an offer came in at a premium - I am open to this to get back my original investment and some profit a(I am still in long run here 3+year. Vax will likely be partnership and other Australian distribution business run on its own accord. just my thoughts. Also it would be great if some posters could disclose if they work for the company- I noticed some comments from some posters that have more information then publically available normal sometimes and strike it off as anecdotal so please be open and honest for fellow posters if involved for benefit of all
AHZ Price at posting:
50.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)